Opaleye Management Inc.
13F Reported Value
ⓘ$1.1B
Holdings
58
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
Opaleye Management Inc. disclosed 58 positions worth $1.1B in its Form 13F-HR for Q2 2026, led by $LQDA (Liquidia Corp) at 17.7% of the equity portfolio, followed by $ETON and $HROW. During the quarter the fund opened 13 new positions and exited 9 — including a new stake in $IMMX and a full exit from $CATX. The portfolio is most concentrated in Healthcare (98.6% of disclosed assets). All figures are sourced directly from Opaleye Management Inc.’s Form 13F-HR filing with the SEC under CIK 1595855.
AI Fund Analysis
ConcentratingSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- 78.3#56
Quality
$195.1M2,447,500 sh - 67.5#363
Quality
$103.5M2,860,000 sh - 40.5#2,101
Quality
$101.9M2,400,000 sh - —
Quality
$62.5M855,000 sh - —
Quality
$53.0M1,439,996 sh - —
Quality
$51.8M390,000 sh - —
Quality
$48.0M3,550,000 sh - —
Quality
$37.1M500,000 sh - —
Quality
$32.8M6,300,000 sh - 69.3
Quality
$29.4M535,000 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Liquidia Corp$LQDA | 78.3#56 | $195.1M | 2,447,500 |
 Eton Pharmaceuticals, Inc.$ETON | 67.5#363 | $103.5M | 2,860,000 |
 HARROW, INC.$HROW | 40.5#2,101 | $101.9M | 2,400,000 |
 Disc Medicine, Inc.$IRON | — | $62.5M | 855,000 |
 UroGen Pharma Ltd.$URGN | — | $53.0M | 1,439,996 |
 Apogee Therapeutics, Inc.$APGE | — | $51.8M | 390,000 |
 MeiraGTx Holdings plc$MGTX | — | $48.0M | 3,550,000 |
 Sol-Gel Technologies Ltd.$SLGL | — | $37.1M | 500,000 |
 Rezolute, Inc.$RZLT | — | $32.8M | 6,300,000 |
 TG THERAPEUTICS, INC.$TGTX | 69.3 | $29.4M | 535,000 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of Opaleye Management Inc.'s 58 positions.
Showing top 10 of 58 holdings.
Sector Allocation
Healthcare
$1.1B
Materials
$15.3M
Full Holdings — Opaleye Management Inc. (Q2 2026)
All 58 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $LQDA | Liquidia Corp | $195.1M | 17.7% | -4% | 78.3 |
| 2 | $ETON | Eton Pharmaceuticals, Inc. | $103.5M | 9.4% | +0% | 67.5 |
| 3 | $HROW | HARROW, INC. | $101.9M | 9.2% | -15% | 40.5 |
| 4 | $IRON | Disc Medicine, Inc. | $62.5M | 5.7% | +103% | — |
| 5 | $URGN | UroGen Pharma Ltd. | $53.0M | 4.8% | +1% | — |
| 6 | $APGE | Apogee Therapeutics, Inc. | $51.8M | 4.7% | +0% | — |
| 7 | $MGTX | MeiraGTx Holdings plc | $48.0M | 4.3% | +67% | — |
| 8 | $SLGL | Sol-Gel Technologies Ltd. | $37.1M | 3.4% | +0% | — |
| 9 | $RZLT | Rezolute, Inc. | $32.8M | 3.0% | +0% | — |
| 10 | $TGTX | TG THERAPEUTICS, INC. | $29.4M | 2.7% | +0% | 69.3 |
| 11 |  $IMMX | Immix Biopharma, Inc. | $24.2M | 2.2% | NEW | — |
| 12 |  $CBIO | CRESCENT BIOPHARMA, INC. | $23.7M | 2.1% | +1% | 9.6 |
| 13 |  $STOK | Stoke Therapeutics, Inc. | $22.9M | 2.1% | +0% | 24.9 |
| 14 |  $ACOG | Alpha Cognition Inc. | $20.9M | 1.9% | +13% | — |
| 15 |  $EWTX | Edgewise Therapeutics, Inc. | $20.3M | 1.8% | +0% | — |
| 16 |  $RVMD | Revolution Medicines, Inc. | $18.7M | 1.7% | +0% | — |
| 17 |  $GLUE | Monte Rosa Therapeutics, Inc. | $18.0M | 1.6% | NEW | 30.3 |
| 18 |  $ALMS | ALUMIS INC. | $15.5M | 1.4% | +0% | 7.1 |
| 19 |  $CDXS | CODEXIS, INC. | $15.3M | 1.4% | +0% | 28.9 |
| 20 |  $REPL | Replimune Group, Inc. | $15.3M | 1.4% | NEW | — |
| 21 |  $XOMA | XOMA Royalty Corp | $14.4M | 1.3% | +13% | 69.7 |
| 22 |  $MBX | MBX Biosciences, Inc. | $14.4M | 1.3% | +0% | — |
| 23 |  $RYTM | RHYTHM PHARMACEUTICALS, INC. | $13.6M | 1.2% | -0% | 33.9 |
| 24 |  $EDIT | Editas Medicine, Inc. | $12.5M | 1.1% | +100% | 33.4 |
| 25 |  $PTGX | Protagonist Therapeutics, Inc | $12.3M | 1.1% | +0% | 59.4 |
| 26 |  $CABA | Cabaletta Bio, Inc. | $12.0M | 1.1% | +180% | — |
| 27 |  $FIXX | Q32 Bio Inc. | $11.9M | 1.1% | -26% | 36.4 |
| 28 |  $ANNX | Annexon, Inc. | $9.8M | 0.9% | -26% | — |
| 29 |  $VSTM | Verastem, Inc. | $6.9M | 0.6% | NEW | 29.7 |
| 30 |  $ZNTL | Zentalis Pharmaceuticals, Inc. | $6.9M | 0.6% | +0% | 11.6 |
| 31 |  $RLMD | RELMADA THERAPEUTICS, INC. | $6.5M | 0.6% | +0% | — |
| 32 |  $OCUL | OCULAR THERAPEUTIX, INC | $5.9M | 0.5% | +0% | 8.4 |
| 33 |  $TRVI | Trevi Therapeutics, Inc. | $5.8M | 0.5% | -10% | — |
| 34 |  $BBOT | BridgeBio Oncology Therapeutics, Inc. | $5.3M | 0.5% | +1214% | — |
| 35 |  $LYEL | Lyell Immunopharma, Inc. | $4.8M | 0.4% | +335% | 9.3 |
| 36 |  $IRD | Opus Genetics, Inc. | $4.6M | 0.4% | +0% | — |
| 37 |  $FDMT | 4D Molecular Therapeutics, Inc. | $4.4M | 0.4% | +198% | 34.5 |
| 38 |  $NTLA | Intellia Therapeutics, Inc. | $4.2M | 0.4% | +2% | 19.9 |
| 39 |  $VYGR | Voyager Therapeutics, Inc. | $4.1M | 0.4% | +3% | 8.1 |
| 40 |  $BDSX | BIODESIX INC | $4.1M | 0.4% | -24% | 35 |
| 41 |  $RCKT | ROCKET PHARMACEUTICALS, INC. | $3.4M | 0.3% | +5% | — |
| 42 |  $JBIO | Jade Biosciences, Inc. | $3.2M | 0.3% | -66% | — |
| 43 |  $SNWV | SANUWAVE Health, Inc. | $3.1M | 0.3% | -69% | 63 |
| 44 |  $FBIO | Fortress Biotech, Inc. | $2.7M | 0.3% | -15% | 59.1 |
| 45 |  $DERM | Journey Medical Corp | $2.5M | 0.2% | -64% | 16.5 |
| 46 |  $PHAT | Phathom Pharmaceuticals, Inc. | $2.0M | 0.2% | NEW | 40.9 |
| 47 |  $INBX | Inhibrx Biosciences, Inc. | $1.9M | 0.2% | NEW | 30 |
| 48 |  $ENTA | ENANTA PHARMACEUTICALS INC | $1.8M | 0.2% | +0% | 17.8 |
| 49 |  $COAG | Hemab Therapeutics Holdings, Inc. | $1.8M | 0.2% | NEW | — |
| 50 |  $TRAX | First Tracks Biotherapeutics, Inc. | $1.3M | 0.1% | NEW | — |
| 51 |  $CGON | CG Oncology, Inc. | $1.3M | 0.1% | -81% | 27 |
| 52 |  $BHVN | Biohaven Ltd. | $1.2M | 0.1% | NEW | — |
| 53 |  $AVIR | Atea Pharmaceuticals, Inc. | $1.1M | 0.1% | -27% | — |
| 54 |  $KTTA | Pasithea Therapeutics Corp. | $1.1M | 0.1% | NEW | — |
| 55 |  $ADCT | ADC Therapeutics SA | $749,000 | 0.1% | NEW | 21.8 |
| 56 |  $OKYO | OKYO Pharma Ltd | $562,806 | 0.1% | NEW | — |
| 57 |  $PTN | PALATIN TECHNOLOGIES INC | $221,195 | 0.0% | NEW | — |
| 58 |  $ADGM | Adagio Medical Holdings, Inc. | $13,353 | 0.0% | +0% | — |
New Positions (13)
$IMMX Immix Biopharma, Inc.$24.2M$GLUE Monte Rosa Therapeutics, Inc.$18.0M$REPL Replimune Group, Inc.$15.3M$VSTM Verastem, Inc.$6.9M$PHAT Phathom Pharmaceuticals, Inc.$2.0M$INBX Inhibrx Biosciences, Inc.$1.9M$COAG Hemab Therapeutics Holdings, Inc.$1.8M$TRAX First Tracks Biotherapeutics, Inc.$1.3M$BHVN Biohaven Ltd.$1.2M$KTTA Pasithea Therapeutics Corp.$1.1M$ADCT ADC Therapeutics SA$749,000$OKYO OKYO Pharma Ltd$562,806$PTN PALATIN TECHNOLOGIES INC$221,195
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for Opaleye Management Inc. including:
Track Opaleye Management Inc.'s Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for Opaleye Management Inc. and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: Opaleye Management Inc.
13F Pro is an AI hedge fund tracker and stock research platform. For Opaleye Management Inc. (SEC CIK: 1595855), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in Opaleye Management Inc.'s portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.